title: Peritoneal Dialysis for Chronic Congestive Heart Failure.
abstract: Maladaptive responses between a failing heart and the kidneys ultimately lead to permanent chronic kidney disease, referred to as cardiorenal syndrome type 2. In this narrative review, we discuss the pathophysiological pathways in the progression of cardiorenal failure and review the current evidence on peritoneal dialysis as a treatment strategy in cardiorenal syndrome type 2. A patient with heart failure can present with clinical symptoms related to venous congestion even in the absence of end-stage renal disease. Diuretics remain the cornerstone for the treatment of fluid overload related to heart failure. However, with chronic use, diuretic resistance can supervene. When medical therapy is no longer able to relieve congestive symptoms, ultrafiltration might be needed. Patients with heart failure tolerate well the gentle rate of fluid removal through peritoneal dialysis. Recent publications suggest a positive impact of starting peritoneal dialysis in patients with cardiorenal syndrome type 2 on the hospitalisation rate, functional status and quality of life.
authors.affiliation: Division of Nephrology, University Health Network Toronto General Hospital, University of Toronto, Toronto, Ont., Canada.
authors.forename: Karlien
authors.initials: K
authors.lastname: François
authors.forename: Claudio
authors.initials: C
authors.lastname: Ronco
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Bargman
mesh_terms: D059347:Cardio-Renal Syndrome / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D002908:Chronic Disease; D006333:Heart Failure / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D010343:Patient Admission; D010530:Peritoneal Dialysis / Q000009:adverse effects / Q000379:methods; D011788:Quality of Life; D012307:Risk Factors; D016896:Treatment Outcome; D014462:Ultrafiltration / Q000379:methods